Open AccessResponse to the article: “Breastfeeding and therapeutic for coronavirus 2019 disease (COVID-19)”
Author(s) -
María José Pontes,
Bruna Cristina Alves,
Chaiana Esmeraldino Mendes Marcon,
Aline Oenning Baggio
Publication year - 2021
Publication title -
residência pediátrica
Language(s) - English
Resource type - Journals
ISSN - 2236-6814
DOI - 10.25060/residpediatr-2021.v11n1-475
Subject(s) - breastfeeding , covid-19 , favipiravir , breast milk , medicine , breast feeding , lactation , coronavirus , drug , pandemic , clinical trial , disease , intensive care medicine , pediatrics , outbreak , pregnancy , virology , pharmacology , infectious disease (medical specialty) , biology , biochemistry , genetics
The editor’s letter aimed to expose the uncertainties and lack of evidence about the new coronavirus regarding breast-feeding from infected mothers and all possible risks in drug testing trials in the mothers and their infants. From comparisons among scientific studies, it was concluded that the vertical transmission is unlikely, and the benefits of breast-feeding outweigh risks of contamination. In addition, when evaluating the intrinsic properties of each drug, it is concluded that most drugs used in COVID-19 therapy are safe in the lactation period. The only exception was favipiravir since there is no solid information in the literature about its excretion in breast milk.